GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elutia Inc (NAS:ELUT) » Definitions » Days Sales Outstanding

Elutia (Elutia) Days Sales Outstanding : 47.73 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Elutia Days Sales Outstanding?

Elutia's average Accounts Receivable for the three months ended in Dec. 2023 was $3.07 Mil. Elutia's Revenue for the three months ended in Dec. 2023 was $5.88 Mil. Hence, Elutia's Days Sales Outstanding for the three months ended in Dec. 2023 was 47.73.

The historical rank and industry rank for Elutia's Days Sales Outstanding or its related term are showing as below:

ELUT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.68   Med: 61.47   Max: 74.76
Current: 48.68

During the past 6 years, Elutia's highest Days Sales Outstanding was 74.76. The lowest was 48.68. And the median was 61.47.

ELUT's Days Sales Outstanding is ranked better than
70.88% of 807 companies
in the Medical Devices & Instruments industry
Industry Median: 63.94 vs ELUT: 48.68

Elutia's Days Sales Outstanding declined from Dec. 2022 (75.73) to Dec. 2023 (47.73).


Elutia Days Sales Outstanding Historical Data

The historical data trend for Elutia's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elutia Days Sales Outstanding Chart

Elutia Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial 61.38 61.55 50.69 74.76 51.90

Elutia Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.73 38.84 60.49 68.51 47.73

Competitive Comparison of Elutia's Days Sales Outstanding

For the Medical Devices subindustry, Elutia's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elutia's Days Sales Outstanding Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Elutia's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Elutia's Days Sales Outstanding falls into.



Elutia Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Elutia's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (3.774 + 3.263) / 2 ) / 24.745*365
=3.5185 / 24.745*365
=51.90

Elutia's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (2.883 + 3.263) / 2 ) / 5.875*365 / 4
=3.073 / 5.875*365 / 4
=47.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elutia  (NAS:ELUT) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Elutia Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Elutia's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Elutia (Elutia) Business Description

Traded in Other Exchanges
N/A
Address
12510 Prosperity Drive, Suite 370, Silver Spring, MD, USA, 20904
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health, Orthobiologics, and Cardiovascular. It generates maximum revenue from the Orthobiologics segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Executives
Elutia Pipe Investment, Lp 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Birchview Fund Llc 10 percent owner 688 PINE STREET, BURLINGTON VT 05401
Thomas Englese officer: Chief Commercial Officer C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING MD 20904
David Colpman director 452 FIFTH AVENUE, NEW YORK NY 10018
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
Matthew Ferguson officer: Chief Financial Officer C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Highcape Partners Gp Ii, Llc 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Gp Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Qp Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Capital, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Michelle Leroux Williams officer: Chief Scientific Officer C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRINT MD 20904
Matthew Strobeck 10 percent owner C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Birchview Capital, Lp 10 percent owner 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON VT 05401
Peter G Edwards officer: GENERAL COUNSEL C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015